Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.

Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021

Open access
Mirzoev, Azamdzhon, Macklin, Grace R, Zhang, Yiting, Mainou, Bernardo A, Sadykova, Umeda, Olsavszky, Victor Stefan, Huseynov, Shahin, Ruziev, Murodali, Saidzoda, Faizali, Bobokhonova, Mahtob, Mach, Ondrej · 2022 · The Lancet Global Health

Abstract

Background Novel oral poliovirus vaccine type 2 (nOPV2) was used to control an outbreak of type 2 circulating vaccine derived poliovirus (cVDPV2) in Tajikistan, in 2021. We measured seroconversion and seroprevalence of type 2 polio antibodies in children who were reported to have received two doses of nOPV2 in outbreak response campaigns. Methods In this community serosurvey, children born after Jan 1, 2016 were enrolled from seven districts in Tajikistan. Dried blood spot cards were collected before nOPV2 campaigns and after the first and second rounds of the campaigns and were sent to the Centers for Disease Control and Prevention (Atlanta, GA, USA) for microneutralisation assay to determine presence of polio antibodies. The primary endpoint was to assess change in seroprevalence and seroconversion against poliovirus serotype 2 after one and two doses of nOPV2. Findings 228 (97%) of 236 enrolled children were included in the analysis. The type 2 antibody seroprevalence was 26% (53/204; 95% CI 20 to 33) before nOPV2, 77% (161/210; 70 to 82) after one dose of nOPV2, and 83% (174/209; 77 to 88) after two doses of nOPV2. The increase in seroprevalence was statistically significant between baseline and after one nOPV2 dose (51 percentage points [42 to 59], p<0·0001), but not between the first and second doses (6 percentage points [–2 to 15], p=0·12). Seroconversion from the first nOPV2 dose, 67% (89/132; 59 to 75), was significantly greater than that from the second nOPV2 dose, 44% (20/45; 30 to 60; χ 2 p=0·010). Total seroconversion after two nOPV2 doses was 77% (101/132; 68 to 83). Interpretation Our study demonstrated strong immune responses following nOPV2 outbreak response campaigns in Tajikistan. Our results support previous clinical trial data on the generation of poliovirus type 2 immunity by nOPV2 and provide evidence that nOPV2 can be appropriate for the cVDPV2 outbreak response. The licensure and WHO prequalification of nOPV2 should be accelerated to facilitate wider use of the vaccine. Funding World Health Organization, Centers for Disease Control and Prevention, and Rotary International.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2214-109x(22)00412-0

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Dates and locations of detection of cVDPV2 isolates in Tajikistan (A) Dates of detection of cVDPV2 isolates in Tajikistan between Nov 1, 2020, and July 31, 2021, from patients with acute flaccid paralysis (n=36) and environmental surveillance samples (n=17). Date of detection represents the date of paralysis onset or date of environmental surveillance sampling. Vertical black lines show the date of nOPV2 outbreak response vaccination campaigns (end date for multi-day campaigns). Dashed lines represent national nOPV2 vaccination campaigns and the dotted line represents the subnational campaign conducted after the timeframe of this study. (B) Location of cVDPV2 detections in Tajikistan from patients with acute flaccid paralysis and environmental surveillance samples, and study areas. Patients with acute flaccid paralysis (red circles), environmental surveillance samples (green squares), and study districts (shaded in grey) are shown. Figure reproduced from data available at WHO headquarters as of July 13, 2021, and reproduced from previous sources.1, 15 cVDPV2=type 2 circulating vaccine derived poliovirus. nOPV2=novel oral poliovirus vaccine type 2.
Figure 1 Dates and locations of detection of cVDPV2 isolates in Tajikistan (A) Dates of detection of cVDPV2 isolates in Tajikistan between Nov 1, 2020, and July 31, 2021, from patients with acute flaccid paralysis (n=36) and environmental surveillance samples (n=17). Date of detection represents the date of paralysis onset or date of environmental surveillance sampling. Vertical black lines show the date of nOPV2 outbreak response vaccination campaigns (end date for multi-day campaigns). Dashed lines represent national nOPV2 vaccination campaigns and the dotted line represents the subnational campaign conducted after the timeframe of this study. (B) Location of cVDPV2 detections in Tajikistan from patients with acute flaccid paralysis and environmental surveillance samples, and study areas. Patients with acute flaccid paralysis (red circles), environmental surveillance samples (green squares), and study districts (shaded in grey) are shown. Figure reproduced from data available at WHO headquarters as of July 13, 2021, and reproduced from previous sources.1, 15 cVDPV2=type 2 circulating vaccine derived poliovirus. nOPV2=novel oral poliovirus vaccine type 2.CC BY · PubMed Central
Figure 2 Study participant flow diagram nOPV2=novel oral poliovirus vaccine type 2.
Figure 2 Study participant flow diagram nOPV2=novel oral poliovirus vaccine type 2.CC BY · PubMed Central
Figure 3 Seroprevalence of poliovirus serotype 1, 2, and 3 neutralising antibodies before nOPV2 campaigns (visit 1), 1 month after the first nOPV2 campaign (visit 2), and 1 month after the second nOPV2 campaign (visit 3) 95% binomial CIs indicated by error bars, and sample size of analysable samples and percentage are shown. nOPV2=novel oral poliovirus vaccine type 2.
Figure 3 Seroprevalence of poliovirus serotype 1, 2, and 3 neutralising antibodies before nOPV2 campaigns (visit 1), 1 month after the first nOPV2 campaign (visit 2), and 1 month after the second nOPV2 campaign (visit 3) 95% binomial CIs indicated by error bars, and sample size of analysable samples and percentage are shown. nOPV2=novel oral poliovirus vaccine type 2.CC BY · PubMed Central
Figure 4 Reverse cumulative distribution curves of antibody titres for poliovirus serotype 2 before nOPV2 campaigns (visit 1), 1 month after the first nOPV2 campaign (visit 2), and 1 month after the second nOPV2 campaign (visit 3) Titres on x axis expressed in log2 scale. Antibody titres range from 2·50 to 10·50 log2. nOPV2=novel oral poliovirus vaccine type 2.
Figure 4 Reverse cumulative distribution curves of antibody titres for poliovirus serotype 2 before nOPV2 campaigns (visit 1), 1 month after the first nOPV2 campaign (visit 2), and 1 month after the second nOPV2 campaign (visit 3) Titres on x axis expressed in log2 scale. Antibody titres range from 2·50 to 10·50 log2. nOPV2=novel oral poliovirus vaccine type 2.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 32

Metadata

Authors
Mirzoev, A., Macklin, G. R., Zhang, Y., Mainou, B. A., Sadykova, U., Olsavszky, V. S., Huseynov, S., Ruziev, M., Saidzoda, F., Bobokhonova, M., & Mach, O.
Affiliations
  • World Health Organization (CH)
  • Centers for Disease Control and Prevention (US)
  • World Health Organization Regional Office for Europe (DK)
Corresponding author
Macklin, Grace R
Venue
The Lancet Global Health
Publisher
Elsevier BV
Published
2022-12
Volume
10
Issue
12
Pages
e1807-e1814
ISSN
2214-109X (ISSN-L)
OpenAlex
W4309107156
Cited by
30
References
25
Citations by year
2026: 3 · 2025: 8 · 2024: 9 · 2023: 9 · 2022: 1
FWCI
4.70
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Global Health (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Centers for Disease Control and Prevention
  • World Health Organization
  • Rotary Foundation
Topics
  • Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
  • Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
Keywords
poliovirus type 2, seroconversion, seroprevalence, polio vaccination campaigns, outbreak response, circulating vaccine-derived poliovirus, Tajikistan, children, dried blood spots, polio eradication, vaccine immunogenicity
MeSH terms
Antibodies, Viral, Child, Humans, Poliomyelitis, Poliovirus Vaccine, Oral, Tajikistan, Seroepidemiologic Studies, Immunization Programs, Poliovirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021. https://app.cochat.ai/papers/10.1016/s2214-109x(22)00412-0
The paper
Mirzoev, A., Macklin, G. R., Zhang, Y., Mainou, B. A., Sadykova, U., Olsavszky, V. S., Huseynov, S., Ruziev, M., Saidzoda, F., Bobokhonova, M., & Mach, O. (2022). Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021. The Lancet Global Health. https://doi.org/10.1016/s2214-109x(22)00412-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.